News Quantified

NERV – minerva neurosciences, inc (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript [Seeking Alpha]

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

Minerva Neurosciences (NASDAQ:NERV) was downgraded by analysts at Wall S

Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors

-5.2%

BEAT

0.0%

BEAT

0.0%

BEAT

0.0%

BEAT

Form 8-K Minerva Neurosciences, For: Feb 03

Form EFFECT Minerva Neurosciences,

Form 424B3 Minerva Neurosciences,

Form SCHEDULE 13G Minerva Neurosciences, Filed by: Vivo Opportunity Fund Holdings, L.P.

Form SCHEDULE 13D/A Minerva Neurosciences, Filed by: Boehringer AG

Top News Gainers

6/21 Form 4 Minerva Neurosciences, For: Jun 19 Filed by: Index Venture Associates IV Ltd 40.2%

3/13 Form 8-K Minerva Neurosciences, For: Mar 12 15.4%

4/27 Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020 10.6%

12/24 Investors flock to neuro drug makers after FDA approves new schizophrenia drug [MarketWatch] 9.4%

7/1 Form 4 Minerva Neurosciences, For: Jun 27 Filed by: DOYLE WILLIAM F 8.9%

8/5 Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates 8.1%

3/2 Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020 7.6%

12/10 Form SC 13G/A Minerva Neurosciences, Filed by: FEDERATED INVESTORS INC /PA/ 7.0%

7/9 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 6.4%

12/20 Minerva Neurosciences Inc (NASDAQ: NERV) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 5.5%

Top News Decliners

10/1 Minerva Neurosciences Announces Update for Three Clinical Trials -28.4%

12/18 Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder -17.9%

10/1 Minerva Neurosciences Inc (NASDAQ: NERV) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock. -15.8%

6/24 UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals [MarketWatch] -15.3%

3/9 Minerva Neurosciences Inc (NASDAQ: NERV) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.6%

10/18 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -10.7%

1/17 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -7.7%

11/4 Q3/2019 9/30/2019 EPS -0.360 ZacksConsensus -0.370 ActVsEst 0.010 - Beat -7.2%

5/21 Form 4 Minerva Neurosciences, For: May 17 Filed by: Index Venture Associates V Ltd -6.9%

2/25 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day